Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling
Open Access
- 1 December 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (12) , e0166913
Abstract
The aim of this study is to investigate whether the beneficial effect of exendin-4 on hepatic steatosis is mediated by β-catenin signaling. After the HepG2 human hepatoma cells were treated with PA for 24 hours, total triglycerides levels were increased in a dose-dependent manner, and the expression levels of perilipin family members were upregulated in cells treated with 400 μM PA. For our in vitro model of hepatic steatosis, HepG2 cells were treated with 400 μM palmitic acid (PA) in the presence or absence of 100 nM exendin-4 for 24 hours. PA increased the expression of lipogenic genes, such as sterol regulatory element-binding protein 1c (SREBP-1c), peroxisome proliferator-activated receptor gamma (PPARγ), stearoyl-CoA desaturase 1 (SCD1), fatty acid synthase (FAS), and acetyl-CoA carboxylase (ACC) and triglyceride synthesis-involved genes, such as diacylglycerol acyltransferase 1 (DGAT1) and diacylglycerol acyltransferase 2 (DGAT2) in HepG2 cells, whereas exendin-4 treatment significantly prevented the upregulation of SREBP-1c, PPARγ, SCD1, FAS, ACC, DGAT1 and DGAT2. Moreover, exendin-4 treatment increased the expression of phosphorylated glycogen synthase kinase-3 beta (GSK-3β) in the cytosolic fraction and the expression of β-catenin and transcription factor 4 (TCF4) in the nuclear fraction. In addition, siRNA-mediated inhibition of β-catenin upregulated the expression of lipogenic transcription factors. The protective effects of exendin-4 on intracellular triglyceride content and total triglyceride levels were not observed in cells treated with the β-catenin inhibitor IWR-1. These data suggest that exendin-4 treatment improves hepatic steatosis by inhibiting lipogenesis via activation of Wnt/β-catenin signaling.Keywords
Funding Information
- National Research Foundation of Korea (KR) (NRF-2013R1A1A2063069)
- Samsung Biomedical Research Institute
This publication has 31 references indexed in Scilit:
- Exendin-4 regulates lipid metabolism and fibroblast growth factor 21 in hepatic steatosisMetabolism, 2014
- A Novel Long-Acting Glucagon-Like Peptide-1 Agonist with Improved Efficacy in Insulin Secretion and β-Cell GrowthEndocrinology and Metabolism, 2014
- Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes MellitusEndocrinology and Metabolism, 2013
- GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver DiseaseDiabetes & Metabolism Journal, 2012
- Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP‐1cDiabetes, Obesity and Metabolism, 2010
- Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitisHepatology, 2010
- Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has A Direct Role in Decreasing Hepatic Steatosis in Vitro by Modulating Elements of the Insulin Signaling PathwayHepatology, 2010
- Hepatic lipid metabolism and non-alcoholic fatty liver diseaseNutrition, Metabolism and Cardiovascular Diseases, 2009
- Exendin‐4, a glucagon‐like protein‐1 (GLP‐1) receptor agonist, reverses hepatic steatosis in ob/ob mice†Hepatology, 2005
- New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1cBiochemical Journal, 2002